Role of allo-SCT for CML in 2010

Bone Marrow Transplantation

Volumn 45, Issue 11, 2010, Pages 1579-1586

  Venepalli, N ^a   Rezvani, K ^b   Mielke, S ^c   Savani, B N ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

allogeneic hematopoietic SCT; CML; imatinib; TKI

Indexed keywords

BUSULFAN; DASATINIB; FLUDARABINE; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; AGE; ALLOGENEIC STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CONGESTIVE HEART FAILURE; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOGENETICS; DONOR LYMPHOCYTE INFUSION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG TREATMENT FAILURE; EARLY INTERVENTION; FLUID RETENTION; GASTROINTESTINAL HEMORRHAGE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; HYPERTRANSAMINASEMIA; LEUKEMIA RELAPSE; LIVER DYSFUNCTION; MYELOABLATIVE CONDITIONING; NAUSEA; OUTCOME ASSESSMENT; PANCYTOPENIA; PERICARDIAL EFFUSION; PERIOPERATIVE PERIOD; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PLEURA EFFUSION; POSTOPERATIVE CARE; PREOPERATIVE CARE; PRIORITY JOURNAL; QT PROLONGATION; REDUCED INTENSITY CONDITIONING; REVIEW; SIBLING; SIDE EFFECT; TREATMENT INDICATION; WEIGHT GAIN;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE;

EID: 78149470287     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.138     Document Type: Review

References (85)

1. Pavlovsky C, Kantarjian H, Cortes JE. First-line therapy for chronic myeloid leukemia: past, present, and future. Am J Hematol 2009; 84: 287-293.
2. Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P et al. Allogeneic hematopoietic stem cell trans-plantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006; 91: 513-521.
3. Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007; 109: 5143-5150. (Pubitemid 46890528)
4. Deininger M, Schleuning M, Greinix H, Sayer HG, Fischer T, Martinez J et al. The effect of prior exposure to imatinib on transplant-relatedmortality. Haematologica 2006; 91: 452-459.
5. Jabbour E, Cortes J, Kantarjian HM, Giralt S, Jones D, Jones R et al. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood 2006; 108: 1421-1423. (Pubitemid 44232047)
6. Lee SJ, Kukreja M, Wang T, Giralt SA, Szer J, Arora M et al. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leuke-mia. Blood 2008; 112: 3500-3507.
7. Oehler VG, Gooley T, Snyder DS, Johnston L, Lin A, Cummings CC et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leuke-mia. Blood 2007; 109: 1782-1789. (Pubitemid 46239615)
8. Weisser M, Schleuning M, Haferlach C, Schwerdtfeger R, Kolb HJ. Allogeneic stem-cell transplantation provides ex-cellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy. Leuk Lymphoma 2007; 48: 295-301. (Pubitemid 46994879)
9. Zaucha JM, Prejzner W, Giebel S, Gooley TA, Szatkowski D, Kalwak K et al. Imatinib therapy prior to myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 2005; 36: 417-424. (Pubitemid 43115029)
10. Maziarz RT. Who with chronic myelogenous leukemia to transplant in the era of tyrosine kinase inhibitors? Curr Opin Hematol 2008; 15: 127-133. (Pubitemid 351323153)
11. O'Brien S, Berman E, Borghaei H, DeAngelo DJ, Devetten MP, Devine S et al. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. J Natl Compr Canc Netw 2009; 7: 984-1023. (Pubitemid 44265403)
12. European LeukemiaNet Update. Recommendations from the European LeukemiaNet for the Management of chronic myeloid leukemia (CML). 2010. Available from: http://www.leukemia-net.org/content/leukemias/cml/ recommendations/.
13. Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. chronic leukemia working party of the European group for blood and marrow transplantation. Lancet 1998; 352: 1087-1092.
14. Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1054-1061.
15. Deininger Mea. Abstract 1126 (therapy poster I): International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. (ASH 2009) 2009.
16. Hehlmann R, Berger U, Pfirrmann M, Heimpel H, Hochhaus A, Hasford J et al. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood 2007; 109: 4686-4692. (Pubitemid 46827759)
17. Jabbour E, Jones D, Kantarjian HM, O'Brien S, Tam C, Koller C et al. Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood 2009; 114: 2037-2043.
18. Muller MC, Cortes JE, Kim DW, Druker BJ, Erben P, Pasquini R et al. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexist-ing BCR-ABL mutations. Blood 2009; 114: 4944-4953.
19. Milojkovic D, Nicholson E, Apperley JF, Holyoake TL, Shepherd P, Drummond MW et al. Early prediction of success or failure using second generation tyrosine kinase inhibitors for chronic myeloid leukemia. Haematologica 2010; 95: 224-231.
20. Kantarjian HM, Cortes J, O'Brien S, Giles FJ, Albitar M, Rios MB et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002; 99: 3547-3553. (Pubitemid 34534521)
21. Stem Cell Trialists' Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005; 23: 5074-5087.
22. Champlin RE, Schmitz N, Horowitz MM, Chapuis B, Chopra R, Cornelissen JJ et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood 2000; 95: 3702-3709.
23. Elmaagacli AH, Basoglu S, Peceny R, Trenschel R, Ottinger H, Lollert A et al. Improved disease-free-survival after transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical unrelated donors in patients with first chronic phase chronic myeloid leukemia. Blood 2002; 99: 1130-1135. (Pubitemid 34547063)
24. Oehler VG, Radich JP, Storer B, Blume KG, Chauncey T, Clift R et al. Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia. Biol Blood Marrow Transplant 2005; 11: 85-92. (Pubitemid 40186204)
25. Meisel R, Laws HJ, Balzer S, Bernbeck B, Kramm C, Schonberger S et al. Comparable long-term survival after bone marrow versus peripheral blood progenitor cell trans-plantation from matched unrelated donors in children with hematologic malignancies. Biol Blood Marrow Transplant 2007; 13: 1338-1345. (Pubitemid 47571034)
26. Remberger M, Ringden O, Blau IW, Ottinger H, Kremens B, Kiehl MG et al. No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood 2001; 98: 1739-1745.
27. Gluckman E, Rocha V, Boyer-Chammard A, Locatelli F, Arcese W, Pasquini R et al. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med 1997; 337: 373-381.
28. Rubinstein P, Carrier C, Scaradavou A, Kurtzberg J, Adamson J, Migliaccio AR et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 1998; 339: 1565-1577. (Pubitemid 28536131)
29. Sanz GF, Saavedra S, Jimenez C, Senent L, Cervera J, Planelles D et al. Unrelated donor cord blood transplantation in adults with chronic myelogenous leukemia: results in nine patients from a single institution. Bone Marrow Transplant 2001; 27: 693-701. (Pubitemid 32409443)
30. Nagamura-Inoue T, Kai S, Azuma H, Takanashi M, Isoyama K, Kato K et al. Unrelated cord blood transplantation in CML: Japan Cord Blood Bank Network analysis. Bone Marrow Transplant 2008; 42: 241-251.
31. Szydlo R, Goldman JM, Klein JP, Gale RP, Ash RC, Bach FH et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol 1997; 15: 1767-1777. (Pubitemid 27209503)
32. Weisdorf DJ, Anasetti C, Antin JH, Kernan NA, Kollman C, Snyder D et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood 2002; 99: 1971-1977. (Pubitemid 34525477)
33. Weisdorf DJ, Nelson G, Lee SJ, Haagenson M, Spellman S, Antin JH et al. Sibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapse. Biol BloodMarrow Transplant 2009; 15: 1475-1478.
34. Arora M, Weisdorf DJ, Spellman SR, Haagenson MD, Klein JP, Hurley CK et al. HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia. J Clin Oncol 2009; 27: 1644-1652.
35. Flomenberg N, Baxter-Lowe LA, Confer D, Fernandez-Vina M, Filipovich A, Horowitz M et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 2004; 104: 1923-1930. (Pubitemid 39297840)
36. Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M et al. High-resolution donor-recipient HLA match-ing contributes to the success of unrelated donor marrow transplantation. Blood 2007; 110: 4576-4583. (Pubitemid 351377826)
37. Clift RA, Buckner CD, Appelbaum FR, Bryant E, Bearman SI, Petersen FB et al. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. Blood 1991; 77: 1660-1665.
38. Porter DL, Collins Jr RH, Hardy C, Kernan NA, Drobyski WR, Giralt S et al. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood 2000; 95: 1214-1221. (Pubitemid 30099829)
39. Crawley C, Szydlo R, Lalancette M, Bacigalupo A, Lange A, Brune M et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis ofprognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005; 106: 2969-2976. (Pubitemid 41565887)
40. Kebriaei P, Detry MA, Giralt S, Carrasco-Yalan A, Anagnos-topoulos A, Couriel D et al. Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia. Blood 2007; 110: 3456-3462. (Pubitemid 350106342)
41. Kerbauy FR, Storb R, Hegenbart U, Gooley T, Shizuru J, Al-Ali HK et al. Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML. Leukemia 2005; 19: 990-997. (Pubitemid 40862010)
42. Krejci M, Mayer J, Doubek M, Brychtova Y, Pospisil Z, Racil Z et al. Clinical outcomes and direct hospital costs of reduced-intensity allogeneic transplantation in chronic myeloid leuke-mia. Bone Marrow Transplant 2006; 38: 483-491. (Pubitemid 44445353)
43. Liu QF, Fan ZP, Zhang Y, Jiang ZJ, Wang CY, Xu D et al. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia. Biol Blood Marrow Transplant 2009; 15: 1376-1385.
44. Luo Y, Lai XY, Tan YM, Shi JM, Zhao YM, Han XY et al. Reduced-intensity allogeneic transplantation combined with imatinib mesylate for chronic myeloid leukemia in first chronic phase. Leukemia 2009; 23: 1171-1174.
45. Olavarria E, Siddique S, Griffiths MJ, Avery S, Byrne JL, Piper KP et al. Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood 2007; 110: 4614-4617. (Pubitemid 351377831)
46. Or R, Shapira MY, Resnick I, Amar A, Ackerstein A, Samuel S et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 2003; 101: 441-445. (Pubitemid 36077561)
47. Ruiz-Arguelles GJ, Gomez-Almaguer D, Morales-Toquero A, Gutierrez-Aguirre CH, Vela-Ojeda J, Garcia-Ruiz-Esparza MA et al. The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter study. Bone Marrow Transplant 2005; 36: 1043-1047. (Pubitemid 43078131)
48. Weisser M, Schleuning M, Ledderose G, Rolf B, Schnittger S, Schoch C et al. Reduced-intensity conditioning using TBI (8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease. Bone Marrow Transplant 2004; 34: 1083-1088. (Pubitemid 40028842)
49. Bacher U, Klyuchnikov E, Zabelina T, Ottinger H, Beelen DW, Schrezenmeier H et al. The changing scene of allogeneic stem cell transplantation for chronic myeloid leukemia-a report from the German Registry covering the period from 1998 to 2004. Ann Hematol 2009; 88: 1237-1247.
50. Bornhauser M, Kroger N, Schwerdtfeger R, Schafer-Eckart K, Sayer HG, Scheid C et al. Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era ofimatinib: a retrospective multicentre study. Eur J Haematol 2006; 76: 9-17.
51. Burke MJ, Trotz B, Luo X, Weisdorf DJ, Baker KS, Wagner JE et al. Imatinib use either pre-or post-allogeneic hemato-poietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients. Bone Marrow Transplant 2009; 44: 169-174.
52. Chen MH, Chiou TJ, Lin PC, Gau JP, Hsu HC, Hsiao LT et al. Comparison of myeloablative and nonmyeloablative hematopoietic stem cell transplantation for treatment of chronic myeloid leukemia. Int J Hematol 2007; 86: 275-281. (Pubitemid 350085819)
53. Holowiecki J, Giebel S, Wojnar J, Krawczyk-Kulis M, Markiewicz M, Holowiecka-Goral A et al. Treosulfan and fludarabine low-toxicity conditioning for allogeneic haemato-poietic stem cell transplantation in chronic myeloid leukaemia. Br J Haematol 2008; 142: 284-292. (Pubitemid 351987321)
54. Kojima R, Kami M, Kanda Y, Kusumi E, Kishi Y, Tanaka Y et al. Comparison between reduced intensity and conventional myeloablative allogeneic stem-cell transplantation in patients with hematologic malignancies aged between 50 and 59 years. Bone Marrow Transplant 2005; 36: 667-674. (Pubitemid 41518708)
55. Le Blanc K, Barrett AJ, Schaffer M, Hagglund H, Ljungman P, Ringden O et al. Lymphocyte recovery is a major determinant of outcome after matched unrelated myeloabla-tive transplantation for myelogenous malignancies. Biol Blood Marrow Transplant 2009; 15: 1108-1115.
56. Linn YC, Phang CY, Lim TJ, Chong SF, Heng KK, Lee JJ et al. Effect of missing killer-immunoglobulin-like receptor ligand in recipients undergoing HLA full matched, non-T-depleted sibling donor transplantation: a single institution experience of 151 Asian patients. Bone Marrow Transplant 2010; 45: 1031-1037.
57. Radich JP, Gooley T, Bensinger W, Chauncey T, Clift R, Flowers M et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood 2003; 102: 31-35. (Pubitemid 36759632)
58. Ringden O, Pavletic SZ, Anasetti C, Barrett AJ, Wang T, Wang D et al. The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood 2009; 113: 3110-3118.
59. Russell JA, Duan Q, Chaudhry MA, Savoie ML, Balogh A, Turner AR et al. Transplantation from matched siblings using once-daily intravenous busulfan/fludarabine with thymoglo-bulin: a myeloablative regimen with low nonrelapse mortality in all but older patients with high-risk disease. Biol Blood Marrow Transplant 2008; 14: 888-895. (Pubitemid 351985026)
60. Valcarcel D, Martino R, Sureda A, Canals C, Altes A, Briones J et al. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies. Eur J Haematol 2005; 74: 144-151. (Pubitemid 40175319)
61. Yakoub-Agha I, Mesnil F, Kuentz M, Boiron JM, Ifrah N, Milpied N et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a pro-spective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol 2006; 24: 5695-5702. (Pubitemid 46631311)
62. Das M, Saikia TK, Advani SH, Parikh PM, Tawde S. Use of a reduced-intensity conditioning regimen for allogeneic trans-plantation in patients with chronic myeloid leukemia. Bone Marrow Transplant 2003; 32: 125-129. (Pubitemid 36903434)
63. Dazzi F, Fozza C. Disease relapse after haematopoietic stem cell transplantation: risk factors and treatment. Best Pract Res Clin Haematol 2007; 20: 311-327. (Pubitemid 46585972)
64. Kantarjian HM, O'Brien S, Cortes JE, Giralt SA, Rios MB, Shan J et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2002; 100: 1590-1595. (Pubitemid 34925133)
65. Carpenter PA, Snyder DS, Flowers ME, Sanders JE, Gooley TA, Martin PJ et al. Prophylactic administration of imatinib after hematopoietic cell tran.splantation for high-risk Philadelphia chromosome-positive leukemia. Blood 2007; 109: 2791-2793.
66. Klyuchnikov E, Kroger N, Brummendorf TH, Wiedemann B, Zander AR, Bacher U. Current status and perspectives of tyrosine kinase inhibitor treatment in the post-transplant period in patients with chronic myeloid leukemia (CML). Biol BloodMarrow Transplant 2010; 16: 301-310.
67. Klyuchnikov E, Schafhausen P, Kroger N, Brummendorf TH, Osanmaz O, Asenova S et al. Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia. Acta Haematol 2009; 122: 6-10.
68. Wright MP, Shepherd JD, Barnett MJ, Nantel SH, Sutherland HJ, Toze CL et al. Response to tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia relapsing in chronic and advanced phase following allogeneic hematopoie-tic stem cell transplantation. Biol Blood Marrow Transplant 2010; 16: 639-646.
69. Olavarria E, Ottmann OG, Deininger M, Clark RE, Bandini G, Byrne J et al. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 2003; 17: 1707-1712. (Pubitemid 37185244)
70. Hess G, Bunjes D, Siegert W, Schwerdtfeger R, Ledderose G, Wassmann B et al. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelo-genous leukemia: results of a prospective phase II open-label multicenter study. J Clin Oncol 2005; 23: 7583-7593. (Pubitemid 46291822)
71. Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007; 109: 58-60. (Pubitemid 46053043)
72. Palandri F, Amabile M, Rosti G, Bandini G, Benedetti F, Usala E et al. Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis. Bone Marrow Transplant 2007; 39: 189-191. (Pubitemid 46178754)
73. Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319-325.
74. Collins Jr RH, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433-444. (Pubitemid 27074209)
75. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-2050.
76. Porter D, Levine JE. Graft-versus-host disease and graft-versus-leukemia after donor leukocyte infusion. Semin Hema-tol 2006; 43: 53-61. (Pubitemid 43063335)
77. Raiola AM, Van Lint MT, Valbonesi M, Lamparelli T, Gualandi F, Occhini D et al. Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions. Bone Marrow Transplant 2003; 31: 687-693. (Pubitemid 36553479)
78. Dazzi F, Szydlo RM, Craddock C, Cross NC, Kaeda J, Chase A et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 2000; 95: 67-71. (Pubitemid 30017226)
79. Savani BN, Montero A, Kurlander R, Childs R, Hensel N, Barrett AJ. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant 2005; 36: 1009-1015. (Pubitemid 41741565)
80. Jabbour E, Cortes JE, Giles FJ, O'Brien S, Kantarjian HM. Current and emerging treatment options in chronic myeloid leukemia. Cancer 2007; 109: 2171-2181. (Pubitemid 46801546)
81. Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006; 12: 908-916. (Pubitemid 44175142)
82. Atallah E, Durand JB, Kantarjian H, Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 2007; 110: 1233-1237. (Pubitemid 47281421)
83. Gambacorti-Passerini C, Tornaghi L, Franceschino A, Piazza R, Corneo G, Pogliani E. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nat Med 2007; 13: 13-14, author reply 5-6. (Pubitemid 46067369)
84. Sohn SK, Kim JG, Kim DH, Lee KB. Cardiac morbidity in advanced chronic myelogenous leukaemia patients treated by successive allogeneic stem cell transplantation with busulphan/cyclophosphamide conditioning after imatinib mesylate administration. Br J Haematol 2003; 121: 469-472.
85. Mauro MJ, Deininger MW. Management ofdrug toxicities in chronic myeloid leukaemia. Best Pract Res Clin Haematol 2009; 22: 409-429.